We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice.
- Authors
Giou-Teng Yiang; Horng-Jyh Harn; Yung-Luen Yu; Sheng- Chuan Hu; Yu-Ting Hung; Chia-Jung Hsieh; Shinn-Zong Lin; Chyou-Wei Wei
- Abstract
Human interleukin-15 (hIL15) has anti-tumor activities, but it is not convenient for tumor treatment because of its short half-life. A gene therapy for mouse lung cancer using an adenovirus vector expressing IL15 has been reported. However, adenovirus vector-mediated gene therapy can provoke cellular toxicity and inflammatory reactions. The recombinant adenovirus-associated vector 2 (rAAV2) is safer due to minimal cellular toxicity and immune response. In order to demonstrate that gene therapy can be used safely and successfully for human cancer treatment, the rAAV2 expressing hIL15 gene (rAAV2-hIL15) is applied for human cervical cancer, HeLa cell, in this study. This study successfully demonstrates that rAAV2-hIL15 can express IL15 with bioactivities in vitro and in vivo. In conclusion, our studies show that human cervical cancers are inhibited on animal model with rAAV2-hIL15 treatment and provide a safer and important reference for human cancer gene therapy.
- Subjects
IMMUNOTHERAPY; INTERLEUKIN-5; CANCER treatment; IMMUNE response; GENE therapy
- Publication
Journal of Biomedical Science, 2009, Vol 16, p1
- ISSN
1021-7770
- Publication type
Article
- DOI
10.1186/1423-0127-16-47